 |
|
|
| |
Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in
hepatitis C patients previously treated with direct-acting antiviral agents (DAA)
|
| |
| |
EASL 2022 June 22-26 London
Christiana Graf1, Julia Dietz1, Beat Müllhaupt2, Peter Buggisch3, Katrin Matschenz3, Jörn Schattenberg4, Christoph Antoni5, Stefan Mauss6, Elena Durmashkina7, Claus Niederau8, Thomas Discher9, Janina Trauth9, Julian Schulze zur Wiesch10, Felix Piecha10, Tobias Müller11, Thomas Berg12, Christoph Neumann-Haefelin13, Christoph Berg14, Stefan Zeuzem1, Christoph Sarrazin1,7
|
| |
|
|
|
|
|
